

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number
WO 2004/012732 A3

(51) International Patent Classification⁷: **A61K 31/4015**,
C07D 207/46, 263/14, A61K 38/06, A61P 9/10

(21) International Application Number:
PCT/EP2003/008495

(22) International Filing Date: 31 July 2003 (31.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02017234.2 31 July 2002 (31.07.2002) EP

(71) Applicant (for all designated States except US): **CHAR-
ITÉ-UNIVERSITÄTSMEDIZIN BERLIN** [DE/DE];
Schumannstrasse 20/21, 10117 Berlin (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STANGL, Verena**
[DE/DE]; Nassauische Strasse 7-8, 10717 Berlin (DE).
STANGL, Karl [DE/DE]; Nassauische Strasse 7-8, 10717
Berlin (DE). **LORENZ, Mario** [DE/DE]; Jablonskistrasse
5, 10405 Berlin (DE).

(74) Agents: **KRAUSS, Jan, B.** et al.; Boehmert & Boehmert,
Pettenkoferstrasse 20-22, 80336 München (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
29 April 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **USE OF A PROTEASOME INHIBITOR IN THE TREATMENT OF ENDOTHELIAL DYSFUNCTION AND/OR IN
A LOW-DOSE PROTEASOME INHIBITOR THERAPY**

(57) Abstract: The present invention relates to the use of a proteasome inhibitor for the manufacture of a medicament for the pre-
vention, onset therapy, acute therapy and/or regression of diseases associated with endothelial dysfunction. The present invention
also relates to the use of a proteasome inhibitor as a low-dose treatment.

WO 2004/012732 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/08495

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/4015 C07D207/46 C07D263/14 A61K38/06 A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/047540 A (BETH ISRAEL HOSPITAL) 5 July 2001 (2001-07-05) *cf. abstract, page 7, lines 19-25, page 8, line 23 bridging with page 9, line 24, experiment 2 on pp. 46/47, claims 1/4/5*	1-10, 13-24
X	WO 99/09006 A (BEHNKE MARK ;ROUSH WILLIAM (US); PLAMONDON LOUIS (US); SOUCY FRANC) 25 February 1999 (1999-02-25) *cf. abstract, page 9, line 15 bridging with page 10, line 2, page 31, line 2, page 41, lines 3-9, example 15 on page 67ff., page 69, lines 1-5, claims 71/72*	1-10, 13-24

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 December 2003

Date of mailing of the international search report

12 03. 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stoltner, A

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-10, 13-24 (PART)

Use of at least on proteasome inhibitor for the manufacture of a medicament for the prevention, onset therapy, acute therapy and/or regression of diseases "associated with endothelial dysfunction", wherein the proteasome inhibitor is selected from a group comprising:

a) naturally occurring proteasome inhibitors comprising peptide derivatives which have a C-terminal epoxy keton structure, beta-lacton-derivatives, aclacinomycin A, lactacystin, clastolactacystin.

2. claims: 1-10, 13-24 (PART)

Use of at least on proteasome inhibitor for the manufacture of a medicament for the prevention, onset therapy, acute therapy and/or regression of diseases "associated with endothelial dysfunction", wherein the proteasome inhibitor is selected from a group comprising:

b) synthetic proteasome inhibitors comprising: modified peptide aldehydes such as N-carbobenzoxy-L-leuciny-L-leuciny-L-leucinal (MG132), or the boric acid derivative of MG232, N-carbobenzoxy-Leu-Nva-H (MG115), N-acetyl-L-leuciny-L-leuciny-L-norleucinal (LLnL), N-carbobenzoxy-Ile-Glu(OBut)-Ala-Leu-H (PS1).

3. claims: 1-10,13-24 (PART)

Use of at least on proteasome inhibitor for the manufacture of a medicament for the prevention, onset therapy, acute therapy and/or regression of diseases "associated with endothelial dysfunction", wherein the proteasome inhibitor is selected from a group comprising:

c) peptides comprising: an alpha,beta-epoxyketone-structure, vinyl-sulfones such as carbobenzoxy-L-leuciny-L-leuciny-L-leucin-vinyl-sulfon or 4-hydroxy-5-iodo-3-nitrophenylacetyl-L-leuciny-L-leuciny-L-leucin-vinyl-sulfon (NLVS).

4. claims: 1-10, 13-24 (PART)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/08495

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0147540	A	05-07-2001	AU 2599001 A	09-07-2001
			CA 2397955 A1	05-07-2001
			EP 1242107 A1	25-09-2002
			WO 0147540 A1	05-07-2001
			US 2004009463 A1	15-01-2004
WO 9909006	A	25-02-1999	AU 749857 B2	04-07-2002
			AU 8906298 A	08-03-1999
			BR 9811304 A	13-11-2001
			CA 2301054 A1	25-02-1999
			CN 1271342 T	25-10-2000
			EP 1021407 A1	26-07-2000
			HU 0002724 A2	28-02-2001
			JP 2001515064 T	18-09-2001
			NZ 503169 A	21-12-2001
			WO 9909006 A1	25-02-1999
			US 6133308 A	17-10-2000
			US 2003191322 A1	09-10-2003
			US 6294560 B1	25-09-2001
			US 2002016355 A1	07-02-2002